Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index; 9 of the 13 sources its claims cite were checked for support.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. METHODS: In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. RESULTS: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. CONCLUSIONS: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
CoChat Summary
TL;DR
In a phase 2/3 multinational trial, two 30-μg doses of BNT162b2 given 21 days apart were 95% effective against laboratory-confirmed Covid-19 in participants 16 years of age or older. The vaccine’s safety profile was characterized mainly by short-term, mild-to-moderate local and systemic reactions, with serious adverse events similar between vaccine and placebo groups.
Key findings
- Among 43,548 randomized participants, 43,448 received injections: 21,720 BNT162b2 and 21,728 placebo. In the efficacy population without prior infection, there were 8 Covid-19 cases in vaccine recipients vs. 162 in placebo recipients, corresponding to 95.0% vaccine efficacy (95% CI, 90.3 to 97.6).
- Among participants with or without evidence of prior SARS-CoV-2 infection, 9 Covid-19 cases occurred in vaccine recipients vs. 169 in placebo recipients, for 94.6% efficacy (95% CI, 89.9 to 97.3).
- Of 10 severe Covid-19 cases with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. Between the first and second doses, vaccine efficacy was 52% (95% CI, 29.5 to 68.4).
- Reactogenicity was mostly mild-to-moderate; common events included injection-site pain, fatigue, and headache. Serious adverse events occurred in 0.6% of vaccine recipients and 0.5% of placebo recipients.
Methods
- Ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial; participants 16 years of age or older were randomly assigned 1:1 to receive two doses, 21 days apart, of 30 μg BNT162b2 or saline placebo.
- Primary end points were efficacy against laboratory-confirmed Covid-19 and safety. Efficacy was estimated as 100×(1−IRR), with a Bayesian beta-binomial model; safety analyses were descriptive.
- The main safety subset included 37,706 participants with a median of at least 2 months of safety data after the second dose; the reactogenicity subset included 8,183 participants.
Limitations
- The paper states that with approximately 19,000 participants per group and a median follow-up of 2 months after the second dose, the trial is not large enough to detect less common adverse events reliably; longer-term adverse events and durability of protection remain to be determined.
- The paper states that ethical and practical barriers prevent following placebo recipients for the planned 2 years once the vaccine is approved and recommended, and that the data do not address whether vaccination prevents asymptomatic infection or establish a correlate of protection.
- The paper states that it does not address prevention of Covid-19 in younger adolescents, children, or pregnant women; the text also makes evident that the main safety subset was 49% female, 83% White, 9% Black or African American, 28% Hispanic or Latinx, with a median age of 52 years, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 3 Not checked · 59 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The favorable safety profile observed during phase 1 testing of BNT162b24,8 was confirmed in the phase 2/3 portion of the trial.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Partly supportedcites [4] Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. DOI: 10.1056/NEJMoa2027906. PMC7583697 33053279 sourceExperimental — accuracy not yet measured
The Introduction reports safety data from the Phase 1 portion of the trial, and the Discussion says those data helped select BNT162b2 for Phase 2/3 evaluation. The Discussion describes Phase 2/3 safety assessment as ongoing; this paper does not report Phase 2/3 results confirming the Phase 1 safety profile. No page numbers are available in our copy. (LLM, conf=0.90)
- Partly supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. sourceExperimental — accuracy not yet measured
The Safety and tolerability section reports no related serious adverse events, grade-4 reactions, or withdrawals due to related adverse events in this phase-I/II study, supporting the description of a favorable early safety profile. The paper does not report phase-2/3 safety results confirming that profile; its Clinical trial design section identifies the presented data as coming from a phase-I/II trial. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the reactogenicity profile of BNT162b2 represented mainly short-term local (i.e., injection site) and systemic responses.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Abstract > Conclusions
What the sources say
- Supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. source
The Safety and tolerability section reports local reactions, predominantly injection-site pain, and systemic reactions including fatigue and headache. It says reactions began within 24 hours and mostly resolved within two or three days, supporting the description of mainly short-term responses. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Severe fatigue was observed in approximately 4% of BNT162b2 recipients, which is higher than that observed in recipients of some vaccines recommended for older adults.12”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Could not verifycites [12] Cowling BJ, Perera RAPM, Valkenburg SA, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clin Infect Dis 2020; 71: 1704- 1714. 31828291 PMC7289658 sourceExperimental — accuracy not yet measured
The Results section reports local reactions and serious adverse events after influenza vaccination, but gives no rate of severe fatigue. Searches for severe fatigue and systemic reactions found no passage in our copy that supports the comparison with BNT162b2 recipients. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cumulative incidence of Covid-19 cases over time among placebo and vaccine recipients begins to diverge by 12 days after the first dose, 7 days after the estimated median viral incubation period of 5 days,10 indicating the early onset of a partially protective effect of immunization.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Supportedcites [10] Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577- 582. 32150748 PMC7081172 source
The Discussion reports a median incubation period of 5.2 days, supporting the approximately five-day estimate to which the citation is attached. The vaccine–placebo divergence is not attributed to this source. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No deaths were considered by the investigators to be related to the vaccine or placebo.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Adverse Events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 69 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [46]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“However, both the Oxford-AstraZeneca and Pfizer vaccines give substantial initial efficacy after a single dose of vaccine against parental strains (∼76 and 89%, respectively)”
From Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera (2021) · cites this paper as Polack et al., 2020
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Most large Covid-19 vaccine efficacy trials have reported notably increased vaccine efficacy against severe versus mild to moderate disease.4–7”
From Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [32]
Experimental — accuracy not yet measured
84 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“although fatigue and headache were also reported by many placebo recipients”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“23% and 24%, respectively, after the second dose, among younger vaccine recipients; 17% and 14% among older recipients”
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citationProspects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Cowling, B. J., Perera, R. A. P. M., Valkenburg, S. A., Leung, N. H. L., Iuliano, A. D., Tam, Y. H., Wong, J. H. F., Fang, V. J., Li, A. P. Y., So, H. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1034 · Cited by 110
Cited by
Items 1,301–1,400 of 15,747
Moyon, Q., Sterlin, D., Miyara, M., Anna, F., Mathian, A., Lhote, R., Ghillani‐Dalbin, P., Breillat, P., Mudumba, S., de Alba, S., et al. (2021) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2021-221097 · Cited by 87
Model-driven mitigation measures for reopening schools during the COVID-19 pandemic
McGee, R. S., Homburger, J. R., Williams, H., Bergstrom, C. T., & Zhou, A. Y. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2108909118 · Cited by 86
Eibensteiner, F., Ritschl, V., Nawaz, F. A., Fazel, S. S., Tsagkaris, C., Kulnik, S. T., Crutzen, R., Klager, E., Völkl-Kernstock, S., Schaden, E., et al. (2021) · Journal of Medical Internet Research · doi:10.2196/28973 · Cited by 83
Safety & effectiveness of COVID-19 vaccines: A narrative review
Chirico, F., da Silva, J. A. T., Tsigaris, P., & Sharun, K. (2022) · The Indian Journal of Medical Research · doi:10.4103/ijmr.ijmr_474_21 · Cited by 104
Development of mRNA vaccines against respiratory syncytial virus (RSV)
Qiu, X., Xu, S., Lu, Y., Luo, Z., Yan, Y., Wang, C., & Ji, J. (2022) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2022.10.001 · Cited by 90
Liu, H., Wei, P., Kappler, J. W., Marrack, P., & Zhang, G. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.825256 · Cited by 98
“Meanwhile, several types of SARSCoV-2 vaccines, such as the traditional inactivated whole virus vaccines (7) and adenoviruses (8, 9) or mRNA vaccine encoding the viral spike (10, 11), have been developed and approved for use to immunize the uninfected people to help them build up longterm immunity against the virus.”
BackgroundWeidenbacher, P. A. B., Sanyal, M., Friedland, N., Tang, S., Arunachalam, P. S., Hu, M., Kumru, O. S., Morris, M. K., Fontenot, J. A., Shirreff, L., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37417-9 · Cited by 85
Fluorinated Lipid Nanoparticles for Enhancing mRNA Delivery Efficiency
Zhang, H., Meng, C., Yi, X., Han, J., Wang, J., Liu, F., Ling, Q., Li, H., & Gu, Z. (2024) · ACS Nano · doi:10.1021/acsnano.3c04507 · Cited by 94
Weak immunogenicity after a single dose of SARS-CoV-2 mRNA vaccine in treated cancer patients
Palich, R., Veyri, M., Marot, S. S., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.04.020 · Cited by 81
Vaccine breakthrough hypoxemic COVID-19 pneumonia in patients with auto-Abs neutralizing type I IFNs
Bastard, P., Vazquez, S. E., Liu, J., Laurie, M. T., Wang, C., Gervais, A., Voyer, T. L., Bizien, L., Zamecnik, C. R., Philippot, Q., et al. (2022) · Science Immunology · doi:10.1126/sciimmunol.abp8966 · Cited by 90
Antibody responses after SARS-CoV-2 vaccination in patients with lymphoma
Lim, S. H., Campbell, N. A., Johnson, M., Joseph‐Pietras, D., Collins, G. P., O'Callaghan, A. M., Fox, C. P., Ahearne, M. J., Johnson, P., Goldblatt, D., et al. (2021) · The Lancet Haematology · doi:10.1016/s2352-3026(21)00199-x · Cited by 81
Therapeutic Applications of Nanomedicine: Recent Developments and Future Perspectives
Rehan, F., Zhang, M., Fang, J. Q., & Greish, K. F. (2024) · Molecules · doi:10.3390/molecules29092073 · Cited by 107
“Following the recent triumph of SARS-CoV-2 vaccinations [118], lipid NPs have gained widespread recognition as genetic material delivery vectors.”
BackgroundVaccine development: Current trends and technologies
Poria, R., Kala, D., Nagraik, R., Walia, Y., Dhir, S., Singh, B., Kaushik, N. K., Noorani, M. S., Kaushal, A., & Gupta, S. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.122331 · Cited by 99
Wang, L., Kaelber, D. C., Xu, R., & Berger, N. A. (2022) · Blood Reviews · doi:10.1016/j.blre.2022.100931 · Cited by 80
Johnson, L. T., Zhang, D., Zhou, K., Lee, S. M., Liu, S., Dilliard, S. A., Farbiak, L., Chatterjee, S., Lin, Y.-H., & Siegwart, D. J. (2022) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.2c00442 · Cited by 88
Status Report on COVID-19 Vaccines Development
Kumar, A., Dowling, W. E., Román, R. G., Chaudhari, A. B., Gurry, C., Le, T. T., Tollefson, S., Clark, C. E., Bernasconi, V., & Kristiansen, P. A. (2021) · Current Infectious Disease Reports · doi:10.1007/s11908-021-00752-3 · Cited by 86
Jo, N., Hidaka, Y., Kikuchi, O., Fukahori, M., Sawada, T., Aoki, M., Yamamoto, M., Nagao, M., Morita, S., Nakajima, T. E., et al. (2023) · Nature Aging · doi:10.1038/s43587-022-00343-4 · Cited by 94
Effectiveness of COVID‐19 vaccines: findings from real world studies
Henry, D. A., Jones, M., Stehlik, P., & Glasziou, P. (2021) · The Medical Journal of Australia · doi:10.5694/mja2.51182 · Cited by 91
“The investigators took the additional step of calibrating their statistical model against the results of the pivotal Phase 3 randomized trial, which found no benefit during the first 2 weeks after vaccination.(2) In contrast, this observational study found lower rates of infection in the first 2 weeks after vaccinatio…”
BackgroundMethodA comprehensive comparison of DNA and RNA vaccines
Wang, C., & Yuan, F. (2024) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2024.115340 · Cited by 105
A look into the future of the COVID-19 pandemic in Europe: an expert consultation
Iftekhar, E. N., Priesemann, V., Balling, R., Bauer, S., Beutels, P., Valdez, A. C., Cuschieri, S., Czypionka, T., Dumpis, U., Glaab, E., et al. (2021) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2021.100185 · Cited by 137
“Importantly, they seem especially likely to prevent severe symptoms and hospitalization, reaching relative risk reductions of about 70 95% [30,32,35-37].”
SARS-CoV-2 Antibodies Detected in Mother’s Milk Post-Vaccination
Baird, J. K., Jensen, S. M., Urba, W. J., Fox, B. A., & Baird, J. R. (2021) · Journal of Human Lactation · doi:10.1177/08903344211030168 · Cited by 86
“Our group found a significant increase in IgA and IgG immunoglobulins in human milk specific to both the SARSCoV-2 viral spike protein and its receptor binding domain starting between Day 7 and Day 14 after vaccination, slightly earlier than previously published. Perl et al. (2021) found a significant increase in SARS…”
ResultCharmet, T., Schaeffer, L., Grant, R., Galmiche, S., Chény, O., Von Platen, C., Maurizot, A., Rogoff, A., Omar, F., David, C., et al. (2021) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2021.100171 · Cited by 80
“These findings align well with results from clinical trials against the original viruses: 95% for BNT162b2 mRNA[24], and 94% for Moderna mRNA-1273[25] vaccines; and with results from field evaluations of BNT162b2 mRNA vaccines: 94% against a mix of original viruses and B.”
Suzuki, Y., Miyazaki, T., Muto, H., Kubara, K., Mukai, Y., Watari, R., Sato, S., Kondo, K., Tsukumo, S., Yasutomo, K., et al. (2022) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2022.09.017 · Cited by 92
Structural basis for continued antibody evasion by the SARS-CoV-2 receptor binding domain
Smith, K. N., Clark, S. A., Shankar, S., Pan, J., Clark, L. E., Yang, P., Coscia, A., McKay, L. G. A., Varnum, H., Brusic, V., et al. (2022) · Science · doi:10.1126/science.abl6251 · Cited by 83
Brodziak, A., Sigorski, D., Osmola, M., Wilk, M., Gawlik-Urban, A., Kiszka, J., Machulska-Ciuraj, K., & Sobczuk, P. (2021) · Vaccines · doi:10.3390/vaccines9050411 · Cited by 82
“The European Society of Medical Oncology (ESMO) released statements concerning COVID-19 vaccination in oncological patients, which supports vaccination, the monitoring of side effects, and education in patients with cancer [17].”
BackgroundWillis, J. R., Berndsen, Z. T., Krystal, M., Steichen, J. M., Schiffner, T., Landais, E., Liguori, A., Kalyuzhniy, O., Allen, J. D., Baboo, S., et al. (2022) · Immunity · doi:10.1016/j.immuni.2022.09.001 · Cited by 79
Moustsen-Helms, I. R., Emborg, H.-D., Nielsen, J., Nielsen, K. F., Krause, T. G., Mølbak, K., Møller, K. L., Berthelsen, A.-S. N., & Valentiner-Branth, P. (2021) · doi:10.1101/2021.03.08.21252200 · Cited by 79
“Median follow-up days (min, max) 53 (1-53) 53 (16-53) -”
Hunter, P. R., & Brainard, J. (2021) · medRxiv · doi:10.1101/2021.02.01.21250957 · Cited by 78
Early cross-coronavirus reactive signatures of humoral immunity against COVID-19
Kapłonek, P., Wang, C., Bartsch, Y. C., Fischinger, S., Gorman, M. J., Bowman, K. A., Kang, J., Dayal, D., Martin, P., Nowak, R. P., et al. (2021) · Science Immunology · doi:10.1126/sciimmunol.abj2901 · Cited by 78
“Among these emerging correlates, antibodies are implicated in both natural resolution of infection (16, 21, 24) and protection after vaccination (25, 26) with antibody-mediated effector functions observed before the evolution of neutralizing antibody activity (3, 27, 28).”
Adverse events after first COVID-19 vaccination in patients with autoimmune diseases
Boekel, L., Kummer, L. Y. L., van Dam, K. P. J., Hooijberg, F., van Kempen, Z. L. E., Vogelzang, E. H., Wieske, L., Eftimov, F., van Vollenhoven, R., Kuijpers, T. W., et al. (2021) · The Lancet Rheumatology · doi:10.1016/s2665-9913(21)00181-8 · Cited by 80
Barmada, A., Klein, J., Ramaswamy, A., Brodsky, N. N., Jaycox, J. R., Sheikha, H., Jones, K. M., Habet, V., Campbell, M., Sumida, T. S., et al. (2023) · Science Immunology · doi:10.1126/sciimmunol.adh3455 · Cited by 83
“…vaccine clinical trials shows both higher efficacy in males compared to females as well as more systemic adverse events (e.g., fever, fatigue, and headache) in younger individuals (1, 3, 135, 136), potentially suggesting heightened immune and/or inflammatory responses in these demographic groups.”
BackgroundPremikha, M., Chiew, C. J., Wei, W. E., Leo, Y. S., Ong, B., Lye, D. C., Lee, V. J., & Tan, K. B. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac288 · Cited by 78
Lipid Nanoparticle Delivery Systems to Enable mRNA-Based Therapeutics
Semple, S. C., Leone, R. D., Barbosa, C., Tam, Y. K., & Lin, P. J. C. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14020398 · Cited by 90
“BioNTech/Pfizer evaluated four different mRNA-LNP products consisting of different three RNA modalities: nucleoside-unmodified (BNT162a), nucleoside-modified (BNT162b), and self-amplifying (BNT162c) (Figure 2).”
BackgroundMethodResultInfluentialBagdonaite, I., Thompson, A. J., Wang, X., Søgaard, M., Fougeroux, C. E., Frank, M., Diedrich, J. K., Yates, J. R., Salanti, A., Vakhrushev, S. Y., et al. (2021) · Viruses · doi:10.3390/v13040551 · Cited by 80
Intracellular Protein Delivery: Approaches, Challenges, and Clinical Applications
Chan, A., & Tsourkas, A. (2024) · BME Frontiers · doi:10.34133/bmef.0035 · Cited by 99
“The advantages of mRNA were demonstrated with the deployment of both the Moderna and Pfizer/BioNTech COVID-19 vaccines [37,38] comprising SARS-CoV-2 spike protein encoding mRNA encapsulated within ionizable lipid nanoparticles (LNPs).”
MethodMcPhedran, R., & Toombs, B. (2021) · Economics Letters · doi:10.1016/j.econlet.2021.109747 · Cited by 85
Mu, Z., Wiehe, K. J., Saunders, K. O., Henderson, R. C., Cain, D. W., Parks, R., Martik, D., Mansouri, K., Edwards, R. J., Newman, A., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110514 · Cited by 84
Ssemaganda, A., Nguyen, H. M., Nuhu, F., Jahan, N., Card, C. M., Kiazyk, S. A. K., Severini, G., Keynan, Y., Su, R., Ji, H., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30913-4 · Cited by 81
Wu, J. T.-Y., La, J., Branch‐Elliman, W., Huhmann, L., Han, S. S., Parmigiani, G., Tuck, D. P., Brophy, M. T., Do, N., Lin, A. Y., et al. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2021.5771 · Cited by 86
Lysosomal-mediated drug release and activation for cancer therapy and immunotherapy
Sun, Y., Sha, Y., Cui, G., Meng, F., & Zhong, Z. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114624 · Cited by 83
Designing lipid nanoparticles using a transformer-based neural network
Chan, A., Kirtane, A. R., Qu, Q. R., Huang, X., Woo, J., Subramanian, D. A., Dey, R., Semalty, R., Bernstock, J. D., Ahmed, T., et al. (2025) · Nature Nanotechnology · doi:10.1038/s41565-025-01975-4 · Cited by 120
“The highest-scoring formulation in each cluster was selected, resulting in ten diverse in silico hits per cell line (Supplementary Tables 17 and 18).”
InfluentialWillingness to get vaccinated against Covid-19 and attitudes toward vaccination in general
Kessels, R., Luyten, J., & Tubeuf, S. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.05.069 · Cited by 96
Optimal Allocation of the Limited COVID-19 Vaccine Supply in South Korea
Shim, E. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10040591 · Cited by 90
HIV mRNA Vaccines—Progress and Future Paths
Mu, Z., Haynes, B. F., & Cain, D. W. (2021) · Vaccines · doi:10.3390/vaccines9020134 · Cited by 88
McMahon, M., O’Dell, G., Tan, J., Sárközy, A., Vadovics, M., Carreño, J. M., Puente‐Massaguer, E., Muramatsu, H., Bajusz, C., Rijnink, W. F., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2206333119 · Cited by 88
Nguyen, T., & Duong, V. (2022) · Encyclopedia · doi:10.3390/encyclopedia2020063 · Cited by 94
Nanoparticles for vaccine and gene therapy: Overcoming the barriers to nucleic acid delivery
Mollé, L. M., Smyth, C. H., Yuen, D., & Johnston, A. P. R. (2022) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1809 · Cited by 100
“…in response to the COVID-19 pandemic. mRNA vaccines can be rapidly tailored to virtually any disease state, as highlighted by the development of two mRNA vaccines against SARS-CoV-2 by Pfizer/BioNTech (BNT162b2; Polack et al., 2020) and Moderna (mRNA1273; Baden et al., 2021) in less than a year.”
BackgroundMethodInfluentialCurrent advances in non‐viral gene delivery systems: Liposomes versus extracellular vesicles
Belhadj, Z., Qie, Y., Carney, R. P., Li, Y., & Nie, G. (2023) · BMEMat · doi:10.1002/bmm2.12018 · Cited by 79
Effectiveness of mRNA-1273 and BNT162b2 Vaccines in Qatar
Abu-Raddad, L. J., Chemaitelly, H., & Bertollini, R. (2022) · New England Journal of Medicine · doi:10.1056/nejmc2117933 · Cited by 79
Eliciting antitumor immunity via therapeutic cancer vaccines
Peng, K., Zhao, X., Fu, Y., & Liang, Y. (2025) · Cellular and Molecular Immunology · doi:10.1038/s41423-025-01316-4 · Cited by 114
Barry, M. A., Temsah, M.-H. A., Aljamaan, F., Saddik, B. A., Al-Eyadhy, A. A., Alenezi, S., Alamro, N., Alhuzaimi, A., Alhaboob, A. A. N., Alhasan, K. A., et al. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.08.083 · Cited by 80
mRNA vaccines: the most recent clinical applications of synthetic mRNA
Kwon, S., Kwon, M., Im, S., Lee, K., & Lee, H. (2022) · Archives of Pharmacal Research · doi:10.1007/s12272-022-01381-7 · Cited by 93
Advances in the design and development of SARS-CoV-2 vaccines
Peng, X., Cheng, J., Gong, H., Yuan, M.-D., Zhao, X., Li, Z., & Wei, D. (2021) · Military Medical Research · doi:10.1186/s40779-021-00360-1 · Cited by 91
Sex and Gender in COVID-19 Vaccine Research: Substantial Evidence Gaps Remain
Vassallo, A. J., Shajahan, S., Harris, K., Hallam, L., Hockham, C., Womersley, K., Woodward, M., & Sheel, M. (2021) · Frontiers in Global Women s Health · doi:10.3389/fgwh.2021.761511 · Cited by 84
COVID-19 vaccine impact in Israel and a way out of the pandemic
Leshem, E., & Wilder‐Smith, A. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01018-7 · Cited by 80
Lam, I. C. H., Zhang, R., Man, K. K. C., Wong, C. K. H., Chui, C. S. L., Lai, F. T. T., Li, X., Chan, E. W., Lau, C. S., Wong, I. C. K., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-45953-1 · Cited by 88
Borbone, N., Piccialli, G., Roviello, G. N., & Oliviero, G. (2021) · Molecules · doi:10.3390/molecules26040986 · Cited by 79
Covid-19: variants and vaccination
Darby, A. C., & Hiscox, J. A. (2021) · BMJ · doi:10.1136/bmj.n771 · Cited by 79
Hitchings, M. D. T., Ranzani, O., Dorión, M., D’Agostini, T. L., de Paula, R. C., de Paula, O. F. P., Villela, E. F. D. M., Torres, M. S. S., de Oliveira, S. B., Schulz, W. L., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26459-6 · Cited by 83
Administration of COVID-19 vaccines in immunocompromised patients
Negahdaripour, M., Shafiekhani, M., Moezzi, S. M. I., Amiri, S., Rasekh, S., Bagheri, A., Mosaddeghi, P., & Vazin, A. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.108021 · Cited by 83
(2021) · doi:10.1101/2021.01.27.428516 · Cited by 378
Targeting neoantigens for cancer immunotherapy
Zhao, X., Pan, X., Wang, Y., & Zhang, Y. (2021) · Biomarker Research · doi:10.1186/s40364-021-00315-7 · Cited by 81
Liang, L.-L., Kuo, H., Ho, H. J., & Wu, C. (2021) · Journal of Global Health · doi:10.7189/jogh.11.05019 · Cited by 87
Discovery of Cyclic Peptide Ligands to the SARS-CoV-2 Spike Protein Using mRNA Display
Norman, A. R., Franck, C., Christie, M., Hawkins, P. M. E., Patel, K., Ashhurst, A. S., Aggarwal, A., Low, J. K. K., Siddiquee, R., Ashley, C. L., et al. (2021) · ACS Central Science · doi:10.1021/acscentsci.0c01708 · Cited by 83
Ralvenius, W. T., Andresen, J. L., Huston, M. M., Penney, J., Bonner, J. M., Fenton, O. S., Langer, R., & Tsai, L. (2024) · Advanced Materials · doi:10.1002/adma.202309225 · Cited by 78
Lipid nanoparticle-based mRNA vaccines in cancers: Current advances and future prospects
Huang, T., Peng, L., Han, Y., Wang, D., He, X., Wang, J., & Ou, C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.922301 · Cited by 107
Interpreting vaccine efficacy trial results for infection and transmission
Lipsitch, M., & Kahn, R. J. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.06.011 · Cited by 88
Tackling COVID-19 with neutralizing monoclonal antibodies
Corti, D., Purcell, L. A., Snell, G., & Veesler, D. (2021) · Cell · doi:10.1016/j.cell.2021.07.027 · Cited by 78
“The rapid spread of the disease has prompted the development of several effective vaccines at an unprecedented pace (Jackson et al., 2020; Polack et al., 2020), as well as the intense research for potential novel treatments, including the reuse of existing drugs approved for other indications.”
(2021) · doi:10.1101/2021.03.11.21253419 · Cited by 1,105
Xiong, X., Yuan, J., Li, M., Jiang, B., & Lu, K. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.700014 · Cited by 77
Vaccination status and COVID-19 related mortality: A hospital based cross sectional study
Muthukrishnan, J., Vardhan, V., Mangalesh, S., Koley, M., Shankar, S., Yadav, A. K., & Khera, A. (2021) · Medical Journal Armed Forces India · doi:10.1016/j.mjafi.2021.06.034 · Cited by 83
“Earlier studies from trials and real world data has shown that vaccinated persons are less likely to have the asymptomatic or symptomatic disease and less hospitalization due to severe disease.(2,6,13,19) Data obtained from the vaccine effectiveness studies for the Astra Zeneca (ChAdOx1 nCoV-19) vaccine have shown upt…”
BackgroundArora, P., Sidarovich, A., Krüger, N., Kempf, A., Nehlmeier, I., Graichen, L., Moldenhauer, A.-S., Winkler, M. S., Schulz, S., Jäck, H.-M., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109825 · Cited by 76
Nanomedicine-based strategies to target and modulate the tumor microenvironment
Mendes, B. B., Sousa, D. P., Conniot, J., & Conde, J. (2021) · Trends in cancer · doi:10.1016/j.trecan.2021.05.001 · Cited by 88
Achiron, A., Mandel, M., Dreyer-Alster, S., Harari, G., Dolev, M., Menascu, S., Magalashvili, D., Flechter, S., Givon, U., Guber, D., et al. (2021) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2021.577746 · Cited by 84
Massa, F., Crémoni, M., Gérard, A. O., Grabsi, H., Rogier, L., Blois, M., Couzin, C., Hassen, N. B., Rouleau, M., Barbosa, S., et al. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103679 · Cited by 88
“In phase 3 trials, mRNA vaccines efficacy rates were higher than 90% after two doses across most demographic subgroups [3,4].”
Stefanski, A., Rincón-Arévalo, H., Schrezenmeier, E. V., Karberg, K., Szelinski, F., Ritter, J., Jahrsdörfer, B., Schrezenmeier, H., Ludwig, C., Sattler, A., et al. (2022) · Arthritis & Rheumatology · doi:10.1002/art.42060 · Cited by 84
“DISCUSSION SARS-CoV-2 vaccines have been approved based on their protection against COVID-19 in clinical trials (5-8).”
BackgroundSeroconversion rate after vaccination against COVID-19 in patients with cancer—a systematic review
Corti, C., Antonarelli, G., Scotté, F., Spano, J., Barrière, J., Michot, J., André, F., & Curigliano, G. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.10.014 · Cited by 83
An Overview of Vaccine Development for COVID-19
Shahcheraghi, S. H., Ayatollahi, J., Aljabali, A. A. A., Shastri, M. D., Shukla, S. D., Chellappan, D. K., Jha, N. K., Anand, K., Katari, N. K., Mehta, M., et al. (2021) · Therapeutic Delivery · doi:10.4155/tde-2020-0129 · Cited by 103
Huang, Y., Borisov, O., Kee, J. J., Carpp, L. N., Wrin, T., Cai, S., Sarzotti‐Kelsoe, M., McDanal, C. B., Eaton, A., Pajón, R., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-03154-6 · Cited by 77
Li, M., Jia, L., Xie, Y., Ma, W., Yan, Z., Liu, F., Deng, J., Zhu, A., Siwei, X., Su, W., et al. (2023) · npj Vaccines · doi:10.1038/s41541-023-00732-9 · Cited by 95
Ravanan, R., Mumford, L. L., Ushiro‐Lumb, I., Callaghan, C. J., Pettigrew, G. J., Thorburn, D., Gardiner, D. D., & Forsythe, J. L. R. (2021) · Transplantation · doi:10.1097/tp.0000000000003908 · Cited by 80
Thrombotic Thrombocytopenia after COVID-19 Vaccination: In Search of the Underlying Mechanism
Rzymski, P., Perek, B., & Flisiak, R. (2021) · Vaccines · doi:10.3390/vaccines9060559 · Cited by 82
Kwan, A. C., Ebinger, J. E., Wei, J., Le, C. N., Oft, J. R., Zabner, R., Teodorescu, D. L., Botting, P. G., Navarrette, J., Ouyang, D., et al. (2022) · Nature Cardiovascular Research · doi:10.1038/s44161-022-00177-8 · Cited by 85
Targeted nonviral delivery of genome editors in vivo
Tsuchida, C. A., Wasko, K. M., Hamilton, J. R., & Doudna, J. A. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2307796121 · Cited by 90
“The rapid development, FDA approval, and widespread deploy - ment of multiple LNP - based mRNA vaccines have unequiv - ocally demonstrated the safety, efficacy, and scalability of this delivery strategy (136, 137).”
BackgroundThe impact of delayed access to COVID-19 vaccines in low- and lower-middle-income countries
Duroseau, B., Kipshidze, N. N., & Limaye, R. J. (2023) · Frontiers in Public Health · doi:10.3389/fpubh.2022.1087138 · Cited by 100
“4 million deaths were averted globally because of COVID-19 vaccination (1).”
BackgroundMethodJangra, S., Vrieze, J. D., Choi, A., Rathnasinghe, R., Laghlali, G., Uvyn, A., Herck, S. V., Nuhn, L., Deswarte, K., Zhong, Z., et al. (2021) · Angewandte Chemie International Edition · doi:10.1002/anie.202015362 · Cited by 80
Self-Amplifying RNA Vaccine Candidates: Alternative Platforms for mRNA Vaccine Development
Schmidt, C., & Schnierle, B. S. (2023) · Pathogens · doi:10.3390/pathogens12010138 · Cited by 88
“Use in the current COVID-19 pandemic has shown that LNP-formulated COVID-19 vaccines have high efficacies and are safe in humans [11,12].”
BackgroundCovid-19 vaccine immunogenicity in people living with HIV-1
Nault, L., Marchitto, L., Goyette, G., Tremblay-Sher, D., Fortin, C., Martel‐Laferrière, V., Trottier, B., Richard, J., Durand, M., Kaufmann, D., et al. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.04.090 · Cited by 81
“COVID-19 mRNA vaccines have been shown to be extremely efficacious in protecting against symptomatic disease, hospitalizations and death [1,2].”
BackgroundSystematic Review of Safety and Efficacy of COVID-19 Vaccines in Patients With Kidney Disease
Glenn, D. A., Hegde, A., Kotzen, E., Walter, E. B., Kshirsagar, A. V., Falk, R. J., & Mottl, A. K. (2021) · Kidney International Reports · doi:10.1016/j.ekir.2021.02.011 · Cited by 83
mRNA Vaccines against SARS-CoV-2: Advantages and Caveats
Echaide, M., Chocarro, L., Bocanegra, A., Blanco, E., Kochan, G. T., & Escors, D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065944 · Cited by 83
“The BNT162b2 vaccine consists of a lipid nanoparticle, which contains an mRNA encoding the full-length spike protein with two proline substitutions (in positions 986 and 987) in the S2 subunit to maintain the protein in the prefusion conformation [22,23].”
BackgroundMoncunill, G., Aguilar, R., Ribes, M., Ortega, N., Rubio, R., Salmerón, G., Molina, M. J., Vidal, M., Barrios, D., Mitchell, R. A., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2021.103805 · Cited by 86
Cook, T. M., & Roberts, J. V. (2021) · Anaesthesia · doi:10.1111/anae.15442 · Cited by 79
Kamacooko, O., Kitonsa, J., Bahemuka, U. M., Kibengo, F., Wajja, A., Basajja, V., Lumala, A., Kakande, A., Kafeero, P., Ssemwanga, E., et al. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18137004 · Cited by 98
Gesese, M. M. (2021) · Infection and Drug Resistance · doi:10.2147/idr.s320771 · Cited by 80
COVID-19 Vaccines: Adenoviral Vectors
Jacob-Dolan, C., & Barouch, D. H. (2021) · Annual Review of Medicine · doi:10.1146/annurev-med-012621-102252 · Cited by 87
BNT162b2 mRNA COVID-19 vaccination in immunocompromised patients: A prospective cohort study
Rahav, G., Lustig, Y., Lavee, J., Benjamini, O., Magen, H., Hod, T., Shem‐Tov, N., Shmueli, E., Merkel, D. G., Ben‐Ari, Z., et al. (2021) · EClinicalMedicine · doi:10.1016/j.eclinm.2021.101158 · Cited by 78
“However, the trials excluded ICPs, as their immune response to vaccination is usually blunted [6].”
Gao, Y., Cai, C., Wullimann, D., Niessl, J., Rivera‐Ballesteros, O., Chen, P., Lange, J., Cuapio, A., Blennow, O., Hansson, L., et al. (2022) · Immunity · doi:10.1016/j.immuni.2022.07.005 · Cited by 79
“…BNT162b2 (Pfizer/BioNTech) and mRNA-1273 (Moderna) vaccines have proven to be highly effective in the general population (Baden et al., 2021; Polack et al., 2020), previous studies on immunocompromised populations have observed weaker or absent humoral immune responses after vaccination…”
InfluentialMachado, B. A. S., Hodel, K. V. S., Fonseca, L. M. D. S., Pires, V. C., Mascarenhas, L. A. B., Andrade, L. P. C. D. S., Moret, M. A., & Badaró, R. J. D. S. (2022) · Vaccines · doi:10.3390/vaccines10040591 · Cited by 90
“Determining the safety profile of a vaccine is a critical step at the global level and is monitored by the WHO along with manufacturers, health officials, and national regulatory agencies [5,6,134], since they are drugs administered in healthy populations.”
BackgroundSun, Y., Wu, X. J., Li, J., Radiom, M., Mezzenga, R., Verma, C. S., Yu, J., & Miserez, A. (2024) · Nature Communications · doi:10.1038/s41467-024-54463-z · Cited by 102
“…to treat various diseases,( 36, 37 ) making significant contributions to the development of therapeutics, including clustered regularly interspaced short palindromic repeats (CRISPR) gene editing tools,( 38, 39 ) COVID-19 vaccines,( 40, 41 ) and chimeric antigen receptor (CAR) T-cell therapies.”
Background
Metadata
- Authors
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., & Gruber, W. C.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- From Fundacion INFANT (F.P.P.) and iTrials-Hospital Militar Central (G.P.M.), Buenos Aires; State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.) — both in New York; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., P.L.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and Centro Paulista de Investigação Clinica, São Paulo (C.Z.) — both in Brazil; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (ÖT., U.Ş.), and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Centre, Karl Bremer Hospital, Cape...
- Corresponding author
- Absalon, Judith
- ORCID
- Polack, Fernando P.
- Thomas, Stephen J.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Moreira, Edson D.
- Zerbini, Cristiano
- Swanson, Kena A.
- Roychoudhury, Satrajit
- Li, Ping
- Cooper, David
- Frenck, Robert W.
- Hammitt, Laura L.
- Türeci, Özlem
- Ünal, Serhat
- Mather, Susan
- Dormitzer, Philip R.
- Şahin, Uğur
- Jansen, Kathrin U.
- Gruber, William C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-31
- Volume
- 383
- Issue
- 27
- Pages
- 2603-2615
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7745181
- OpenAlex
- W3111255098
- Cited by
- 14,592
- References
- 8
- Citations by year
- 2026: 756 · 2025: 1216 · 2024: 1543 · 2023: 2310 · 2022: 4192 · 2021: 4494 · 2020: 77
- FWCI
- 362.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- Repositorio Académico UPC (Universidad Peruana de Ciencias Aplicadas) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- BioNTech and Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, severe COVID-19 prevention, two-dose regimen, serious adverse events, subgroup analysis, immunogenicity, immunocompromised patients, pregnant and lactating women
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Fatigue, Female, Headache, Humans, Immunization, Secondary, Male, Middle Aged, Vaccines, Synthetic, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.